Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ceftazidime-Avibactam plus Aztreonam Cocktail for the Treatment of VIM-Producing Pseudomonas aeruginosa Infections.

ABSTRACT: Ceftazidime-Avibactam plus Aztreonam for the Treatment of VIM-Producing Pseudomonas aeruginosa Infections.

PROVIDER: PRJEB81449 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR13851763_1.fastq.gz	Fastqsanger.gz
	ERR13851763_2.fastq.gz	Fastqsanger.gz
	ERR13851764_1.fastq.gz	Fastqsanger.gz
	ERR13851764_2.fastq.gz	Fastqsanger.gz
	ERR13851768_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Whole-Genome Sequencing of Ceftazidime-Avibactam resistant KPC-producing Klebsiella pneumoniae strains

Project description:Emergence of Ceftazidime-Avibactam resistant KPC-producing K. pneumoniae (KPC-Kp) during ceftazidime-avibactam-based antimicrobial treatment.

| PRJEB21871 | ENA

Susceptibility to ceftazidime/avibactam in German MDR/XDR Pseudomonas aeruginosa

Project description:Susceptibility to ceftazidime/avibactam in German MDR/XDR Pseudomonas aeruginosa

| PRJEB30639 | ENA

Multi-omics, multi assay analysis of evolved resistance to ceftazidime-avibactam in Pseudomonas aeruginosa, compared to meropenem resistance and co-resistance evolution

Project description:Pseudomonas aeruginosa is a major cause of infection in hospitalised patients, with a large genome which makes it highly versatile and resistant to most antimicrobial agents. Ceftazidime-avibactam (CZA) offers an alternative treatment, but resistance is quickly evolving. There is limited knowledge on the exact resistance mechanisms to this drug, or on cross-resistance to meropenem (MEM). This laboratory experiment aimed to decipher these mechanisms in order to provide guidance for the best treatment choice in meropenem pre-treated P. aeruginosa infections. Six clinical isolates of P. aeruginosa were subjected to multistep resistance selection in sub inhibitory concentrations of CZA and MEM. MICs were also determined in the presence of the efflux pump inhibitor phenyl-Arginine-β-Naphthylamide (PAβN). Molecular analyses were performed by whole genome sequencing, whole -gene- and -protein expression profiles. CRISPR/Cas9 genome editing was performed using a two-plasmid method for selected mutations

2025-05-21 | PXD044998 | Pride

Novel Mechanisms of Antibiotic Resistance in Mismatch Repair-Deficient Pseudomonas aeruginosa hypermutators

Project description:Using in vitro directed evolution, we show that mismatch repair-deficient Pseudomonas aeruginosa can engage novel resistance mechanisms to ceftazidime-avibactam.

2021-08-30 | GSE180086 | GEO

Transcriptomics analysis during the transient ceftazidime tolerance of Burkholderia pseudomallei

Project description:B. pseudomallei strain K96243 is sensitive to the drug ceftazidime (CAZ), but has been shown to exhibit transient CAZ tolerance when in a biofilm form. To investigate an observed shift in gene expression profile during ceftazidime (CAZ) tolerance and to better understand the mechanistic aspects of this transient tolerance, RNA-sequencing was performed on B. pseudomallei K96243 from the following three growth states: planktonic-free, biofilm, and planktonic shedding cells. Results indicated that the expression of 651 genes (10.97%) were significantly changed in both biofilm (resistant) and planktonic shedding (sensitive) cells in comparison to the planktonic state. Burkholderia biofilm shifts its transcriptome in response to ceftazidime exposure by regulating iron-sulfur stabilizing and metabolic-related genes.

2021-06-30 | GSE168275 | GEO

Laboratory-selected mutants of Enterobacteriaceae with resistance or diminished susceptibility to ceftazidime/avibactam

Project description:Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC- producing Enterobacteriaceae

| PRJEB27344 | ENA

Synergy between mecillinam and ceftazidime/avibactam or avibactam against multi-drug resistant carbapenemase-producing Escherichia coli and Klebsiella pneumoniae.

Project description:Mecillinam/avibactam synergy

| PRJEB50806 | ENA

A multi-omic study of ceftazidime-avibactam resistance mechanisms in pseudomonas aeruginosa

Project description:Multi-omics Profiling of Cross-resistance between Ceftazidime-Avibactam and Meropenem identifies common and Strain-specific Mechanisms in Pseudomonas aeruginosa Clinical Isolates

| PRJEB76120 | ENA

Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa

Project description:Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa

| PRJEB85283 | ENA

Systematic evaluation of in vitro pharmacodynamic drug interactions of ceftazidime/avibactam and fosfomycin in E. coli

Project description:Systematic evaluation of in vitro pharmacodynamic drug interactions of ceftazidime/avibactam and fosfomycin in E. coli

| PRJEB60842 | ENA